Tildrakizumab: Efficacy, Safety and Survival in Mid-Term (52 Weeks) in Three Tertiary Hospitals in Andalucia (Spain)

Tildrakizumab: Efficacy, Safety and Survival in Mid-Term (52 Weeks) in Three Tertiary Hospitals in Andalucia (Spain)

Tildrakizumab (TIL) binds selectively to the p19 subunit of interleukin 23. Its introduction has managed to increase the levels of efficacy, safety (improving that previously presented by the anti-IL-12/23 class) and survival. Retrospective analysis of a multicenter, observational study of real clin...

Full description

Bibliographic Details
Main Authors: Ricardo Ruiz-Villaverde, Lourdes Rodriguez Fernandez-Freire, Pilar Font-Ugalde, Manuel Galan-Gutierrez
Format: Article
Language:English
Published: MDPI AG 2022-08-01
Series:Journal of Clinical Medicine
Subjects:
psoriasis
biological therapy
treatment
Online Access:https://www.mdpi.com/2077-0383/11/17/5098

Similar Items

Similar Items